Deloncle et al., 2022 - Google Patents
Copper acetate aerosols: a possible tool complementary to vaccination in fight against SARS-CoV-2 and variants replicationDeloncle et al., 2022
View HTML- Document ID
- 17094291893790597602
- Author
- Deloncle R
- Guillard O
- Pineau A
- Lesage G
- Publication year
- Publication venue
- Medical Hypotheses
External Links
Snippet
Abstract In SARS-CoV-2, at the S1/S2 furin cleavage site, a four amino acid insert (PRRA) not found in closely related corona viruses, has been shown to facilitate entry into respiratory epithelial cells and promote virus transmission, infectivity and virulence. By cupric aerosol …
- 239000000443 aerosol 0 title abstract description 35
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P-C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yokel et al. | Aluminium toxicokinetics: an updated minireview | |
| Sears | Chelation: harnessing and enhancing heavy metal detoxification—a review | |
| Nriagu | Zinc toxicity in humans | |
| Wang et al. | Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy | |
| US8247398B2 (en) | Zinc complexes of natural amino acids for treating elevated copper caused toxicities | |
| Strunecka et al. | Fluoride interactions: from molecules to disease | |
| CN101610772B (en) | Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination | |
| JP2009526029A (en) | (Metal-containing) virucidal composition and use | |
| ME02335B (en) | ACTIVIN ACTRII ANTAGONISTS AND THEIR USES FOR THE TREATMENT OF ANEMIA | |
| TNSN00256A1 (en) | NON-PEPTIDE INHIBITORS OF VLA-4 DEPENDENT CELL LINKAGE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES, AND COMPOSITIONS CONTAINING THEM | |
| Deloncle et al. | Copper acetate aerosols: a possible tool complementary to vaccination in fight against SARS-CoV-2 and variants replication | |
| PL1633376T3 (en) | Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc | |
| TWI309162B (en) | Amino acid composition for improving functional disorder of liver | |
| AU2024219419A1 (en) | Preparations for the prevention of illnesses acquired via the oral cavity and pharynx | |
| WO2021167032A1 (en) | Drug and food for treating and/or preventing enteritis and/or hepatitis | |
| Insignares-Carrione et al. | Chlorine dioxide in COVID-19: hypothesis about the possible mechanism of molecular action in SARS-CoV-2 | |
| US6114387A (en) | Pharmaceutical composition for oral administration of chelating agents | |
| Kasprzak et al. | Nickel toxicity and carcinogenesis | |
| Habib et al. | Hepatoprotective role of swimming against arsenic induced oxidative stress in mice | |
| Adhikari et al. | COVID‐19 into Chemical Science Perspective: Chemical Preventive Measures and Drug Development | |
| Tatzber et al. | Improved protection of filtering facepiece through inactivation of pathogens by hypertonic salt solutions–A possible COVID-19 prevention device | |
| WO2022178922A1 (en) | Interleukin-29 mutant protein preparation | |
| Boretti et al. | Potential effects of iodine supplementation on inflammatory processes and toxin removal following COVID-19 vaccination | |
| Siddiqi et al. | Effect of different doses of Sodium Fluoride on various hydroxyproline fractions in rat serum | |
| WO2021049980A1 (en) | Novel compositions for treatment and prophylaxis of viral diseases |